Home Knowledge Center Contact Us Back Office Login CareersCustomer Relation e-IPO Online e-KYC Investor Charter eVoting
MF Portfolio Viewer Cyber Security Awareness Campaign Wealth Debut
ABOUT US PRODUCT & SERVICES MARKETSCurrency Derivatives MUTUAL FUNDIpo Downloads ONLINE UPDATION OF NOMINEE
CLOSE
BSE NSE
   IPO Current Issues
Current Issues
Forthcoming Issues
Closed Issues
New Listings
Best Performers
IPO Performance
IPO News
Basis of Allotment
Draft Prospectus
 




Company Name
 
Face Value
(Rs.)
Price Band
(Rs.)
Issue Size
(Rs. In Cr.)
Issue Type
 
Open Date-
Close Date
Min Nos.of
Shares
  Sotac Pharmaceutical 10 105 - 111   31.50 - 33.30     Book building   29-Mar-23  
03-Apr-23   		  1200  
  MOS Utility 10 72 - 76   47.34 - 49.97     Book building   31-Mar-23  
06-Apr-23   		  1600  
  Infinium Pharmachem 10 135   25.3125     Fixed Price   31-Mar-23  
05-Apr-23   		  1000  
  Sancode Technologies 10 47   5.1465     Fixed Price   31-Mar-23  
06-Apr-23   		  3000  
  Exhicon Events Media 10 61 - 64   20.13 - 21.12     Book building   31-Mar-23  
05-Apr-23   		  2000  
Page 1 of 1
Prev || Next

Investor Grievances| Feed Back | Disclaimer | Privacy Policy | Terms Of Use | FAQ | Scores | Refund Policy

Equity SEBI Registration No INZ000204433, NSE Membership No. 07724, BSE Membership No. 3029, SEBI Registration No. for DP: IN-DP-NSDL-11099, NSDL-DP ID: IN301209.
copyright © 2011 bbinvestments.in. all rights reserved.
Useful links:SEBI |NSE |BSE |NCDEX | NSDL | MCX |MCX-SX

SEBI Research Analysts Registration No :INH100007310

Compliance Officer – Mr. Sanjay Rajora,Email Id:- Compliance@bharatbhushan.com Designed, Developed & Content Powered by : Accord Fintech Pvt. Ltd.


close X

Download Client Registration Documents

Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language :

NOTE : " This document is a translated version of the client registration documents in English and is being provided in vernacular language to facilitate better understanding by the investors. In case of any ambiguity, the contents of the English version would prevail. "